Isodiol International Acquires Global Rights to produce products under an Innovative Delivery System Patent
18 November 2017 - 1:25AM
Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF)
(FSE:LB6A.F)
(the “Company” or “Isodiol”), a
global Bioactive Phytoceutical innovator specializing in the
development of pharmaceutical and nutraceutical products, announced
today that it has acquired international licensing rights for
IsoDerm™ as well as five other proprietary pharmaceutical compounds
to be delivered by the patented Direct Effects Technology™, a back
of the neck delivery system from its developer Dr. Ronald Aung-Din,
MD. Dr. Aung-Din is a board-certified neurologist by the American
Board of Psychiatry and Neurology and a recognized leader in
Cannabidiol (CBD) research and its neurological benefits.
With this revolutionary non-systemic delivery system, a topical
cream can be applied to the back of the neck (at the hairline)
which is then picked up by the free nerve endings located in the
dermis of the skin for a highly effective delivery of the
compound.
“We are pleased to be moving forward with this long-anticipated
transaction that gives Isodiol the international rights to the
patent for specific compounds,” said Marcos Agramont, CEO of
Isodiol. “We utilize the back of neck technology in our IsoDerm
Direct Effects Cream where it has proven to be an extremely
effective method of delivering fast relief from neurologic,
psychiatric and pain conditions, without concerns of systemic side
effects and drug interactions. We look forward to incorporating Dr.
Aung-Din’s technologies in the development of a pipeline of
products that may have significant application in the treatment of
conditions that include Parkinson’s Disease, Peripheral Neuropathy,
Cluster Headaches and other significant conditions. We continue to
sponsor Dr. Aung-Din’s remarkable work in Autism and will continue
our efforts to support the families affected by this
condition.”
The Company is required to pay a one time licensing fee of
$300,000 USD payable over 180 days along with continued minimum
royalty payments predicated on product and territories.
For more information on Isodiol, please visit
www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader
in pharmaceutical and nutraceutical grade phytochemical compounds
and the industry leader in the manufacturing and development of
phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry
including commercialization of 99%+ pure, bioactive pharmaceutical
grade cannabinoids, micro-encapsulations, and nanotechnology for
the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of
over-the-counter and pharmaceutical drugs, expanding its
phytoceutical portfolio and will aggressively continue
international expansion into Latin America, Asia and Europe.
Join Us On Facebook:
https://www.facebook.com/isodiol/Twitter:
@isodiol
ON BEHALF OF THE BOARDMarcos Agramont, CEO
& Director
INVESTOR
RELATIONS:Ir@isodiol.comwww.isodiol.com
MEDIA CONTACT:Carrie Booze North 6th Agency
212-334-9753 ext.142 Isodiol@n6a.com
Forward-Looking Information:
This news release contains "forward-looking information" within the
meaning of applicable securities laws relating to statements
regarding the Company's business, products and future of the
Company’s business, its product offerings and plans for sales and
marketing. Although the Company believes that the expectations
reflected in the forward-looking information are reasonable, there
can be no assurance that such expectations will prove to be
correct. Readers are cautioned to not place undue reliance on
forward-looking information. Such forward looking statements are
subject to risks and uncertainties that may cause actual results,
performance and developments to differ materially from those
contemplated by these statements depending on, among other things,
the risks that the Company's products and plan will vary from those
stated in this news release and the Company may not be able to
carry out its business plans as expected. Except as required by
law, the Company expressly disclaims any obligation, and does not
intend, to update any forward-looking statements or forward-looking
information in this news release. Although the Company believes
that the expectations reflected in the forward-looking information
are reasonable, there can be no assurance that such expectations
will prove to be correct and makes no reference to profitability
based on sales reported. The statements in this news release are
made as of the date of this release.
The CSE has not reviewed, approved or disapproved
the content of this press release.